See more : Midland Capital Holdings Corp. (MCPH) Income Statement Analysis – Financial Results
Complete financial analysis of Bristol-Myers Squibb Company (BMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bristol-Myers Squibb Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Taliang Technology Co., Ltd. (3167.TW) Income Statement Analysis – Financial Results
- The Siam Cement Public Company Limited (TCM1.F) Income Statement Analysis – Financial Results
- River Financial Corporation (RVRF) Income Statement Analysis – Financial Results
- YHN Acquisition I Limited Right (YHNAR) Income Statement Analysis – Financial Results
- Plásticos Compuestos, S.A. (ALKOM.PA) Income Statement Analysis – Financial Results
Bristol-Myers Squibb Company (BMY)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.01B | 46.16B | 46.39B | 42.52B | 26.15B | 22.56B | 20.78B | 19.43B | 16.56B | 15.88B | 16.39B | 17.62B | 21.24B | 19.48B | 18.81B | 20.60B | 19.35B | 17.91B | 19.21B | 19.38B | 20.89B | 18.12B | 19.42B | 18.22B | 20.22B | 18.28B | 16.70B | 15.07B | 13.77B | 11.98B | 11.41B | 11.16B | 11.16B | 10.30B | 9.19B | 8.56B | 7.56B |
| Cost of Revenue | 10.69B | 10.14B | 9.94B | 11.77B | 8.08B | 6.55B | 6.07B | 4.95B | 3.91B | 3.93B | 4.62B | 4.61B | 5.60B | 5.28B | 5.14B | 6.40B | 6.22B | 5.96B | 5.93B | 5.99B | 7.59B | 6.39B | 5.58B | 4.01B | 4.86B | 4.23B | 3.87B | 3.45B | 3.19B | 2.79B | 2.72B | 2.56B | 2.68B | 2.63B | 2.46B | 2.30B | 2.14B |
| Gross Profit | 34.31B | 36.02B | 36.45B | 30.75B | 18.07B | 16.01B | 14.71B | 14.48B | 12.65B | 11.95B | 11.77B | 13.01B | 15.65B | 14.21B | 13.67B | 14.20B | 13.13B | 11.96B | 13.28B | 13.39B | 13.30B | 11.73B | 13.85B | 14.20B | 15.36B | 14.05B | 12.83B | 11.62B | 10.58B | 9.19B | 8.69B | 8.59B | 8.48B | 7.67B | 6.73B | 6.26B | 5.42B |
| Gross Profit Ratio | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 70.98% | 70.80% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | 68.95% | 67.86% | 66.75% | 69.14% | 69.10% | 63.66% | 64.74% | 71.30% | 77.97% | 75.96% | 76.86% | 76.81% | 77.13% | 76.84% | 76.69% | 76.16% | 77.03% | 75.95% | 74.47% | 73.23% | 73.14% | 71.67% |
| Research & Development | 9.30B | 9.51B | 10.20B | 11.14B | 6.15B | 6.35B | 6.41B | 4.94B | 5.92B | 4.53B | 3.73B | 3.90B | 3.84B | 3.57B | 3.65B | 3.59B | 3.28B | 3.07B | 2.75B | 2.50B | 2.28B | 2.22B | 2.26B | 1.94B | 1.84B | 1.58B | 1.39B | 1.28B | 1.20B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 162.00M | 91.00M | 160.00M | 877.00M | 165.00M | 158.00M | 4.20B | 3.56B | 4.08B | 4.83B | 4.86B | 4.92B | 5.11B | 5.02B | 4.66B | 3.92B | 3.90B | 3.86B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.40B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.69B | 4.91B | 4.84B | 4.82B | 4.94B | 5.02B | 957.00M | 977.00M | 1.14B | 1.55B | 1.47B | 1.35B | 1.48B | 1.41B | 1.42B | 1.30B | 1.43B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.77B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.85B | 5.00B | 5.00B | 5.70B | 5.10B | 5.18B | 5.16B | 4.54B | 5.21B | 6.38B | 6.32B | 6.27B | 6.58B | 6.43B | 6.08B | 5.22B | 5.34B | 5.53B | 6.99B | 6.73B | 6.41B | 5.87B | 5.32B | 4.53B | 5.98B | 6.34B | 5.46B | 5.04B | 5.45B | 4.30B | 3.79B |
| Other Expenses | 0.00 | 9.60B | 10.02B | 9.76B | 1.14B | 1.37B | 1.40B | 1.00B | 621.00M | 313.00M | 133.00M | 245.00M | 0.00 | 284.00M | -931.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| Operating Expenses | 34.31B | 26.92B | 27.91B | 28.57B | 12.15B | 10.90B | 11.26B | 9.94B | 10.92B | 10.23B | 8.84B | 9.08B | 8.61B | 7.71B | 8.86B | 8.48B | 9.60B | 9.34B | 9.33B | 8.93B | 8.36B | 7.44B | 7.60B | 8.22B | 9.51B | 8.93B | 8.39B | 7.67B | 6.96B | 5.97B | 6.29B | 6.63B | 5.71B | 5.28B | 5.65B | 4.49B | 3.95B |
| Cost & Expenses | 27.76B | 37.06B | 37.85B | 40.34B | 20.23B | 17.44B | 17.33B | 14.89B | 14.83B | 14.17B | 13.45B | 13.69B | 14.21B | 12.98B | 14.00B | 14.88B | 15.82B | 15.29B | 15.26B | 14.92B | 15.95B | 13.82B | 13.17B | 12.23B | 14.37B | 13.16B | 12.26B | 11.11B | 10.15B | 8.76B | 9.01B | 9.20B | 8.39B | 7.91B | 8.11B | 6.79B | 6.09B |
| Interest Income | 0.00 | 171.00M | 120.00M | 121.00M | 464.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91.00M | 75.00M | 54.00M | 130.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.17B | 1.23B | 1.33B | 1.42B | 656.00M | 183.00M | 196.00M | 167.00M | 184.00M | 203.00M | 199.00M | 182.00M | 145.00M | 145.00M | 184.00M | 310.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.81B | 10.29B | 10.76B | 10.49B | 1.81B | 703.00M | 872.00M | 626.00M | 376.00M | 467.00M | 763.00M | 681.00M | 801.00M | 744.00M | 707.00M | 816.00M | 892.00M | 927.00M | 929.00M | 909.00M | 789.00M | 735.00M | 781.00M | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| EBITDA | 19.37B | 19.23B | 20.19B | 5.04B | 7.44B | 6.85B | 6.20B | 4.63B | 2.94B | 3.41B | 4.40B | 3.51B | 7.93B | 7.09B | 6.61B | 6.60B | 4.42B | 3.31B | 4.67B | 5.37B | 5.72B | 4.84B | 5.89B | 6.73B | 5.92B | 5.08B | 5.03B | 4.47B | 4.06B | 3.55B | 2.71B | 2.26B | 3.01B | 2.63B | 1.28B | 1.96B | 1.63B |
| EBITDA Ratio | 43.03% | 43.16% | 43.51% | 34.85% | 25.24% | 26.91% | 27.52% | 28.91% | 14.70% | 13.44% | 19.71% | 24.74% | 33.54% | 33.75% | 22.92% | 28.99% | 24.59% | 21.12% | 23.16% | 28.31% | 28.37% | 35.29% | 52.78% | 40.01% | 32.61% | 35.73% | 29.78% | 29.40% | 38.63% | 35.64% | 21.78% | 19.53% | 25.41% | 23.70% | 11.12% | 20.60% | 18.72% |
| Operating Income | 17.24B | 10.33B | 10.16B | 5.13B | 5.46B | 5.12B | 3.45B | 4.54B | 1.73B | 1.71B | 2.93B | 3.93B | 6.65B | 5.61B | 5.74B | 4.24B | 3.53B | 2.62B | 3.95B | 4.46B | 4.95B | 4.30B | 6.25B | 5.99B | 5.85B | 5.12B | 4.44B | 3.95B | 3.62B | 3.22B | 2.40B | 1.96B | 2.77B | 2.39B | 1.08B | 1.77B | 1.47B |
| Operating Income Ratio | 38.31% | 22.37% | 21.90% | 12.06% | 20.90% | 22.69% | 16.61% | 23.36% | 10.45% | 10.79% | 17.89% | 22.31% | 31.29% | 28.77% | 30.51% | 20.59% | 18.23% | 14.63% | 20.57% | 23.03% | 23.68% | 23.70% | 32.19% | 32.86% | 28.94% | 28.01% | 26.57% | 26.24% | 26.26% | 26.88% | 21.05% | 17.57% | 24.79% | 23.19% | 11.79% | 20.68% | 19.41% |
| Total Other Income/Expenses | -8.80B | -10.64B | -9.30B | -7.42B | -938.00M | -426.00M | -108.00M | 1.45B | 347.00M | 667.00M | -40.00M | -1.59B | 344.00M | 121.00M | 163.00M | -247.00M | 6.00M | 610.00M | 353.00M | -46.00M | -612.00M | -1.60B | -2.94B | -508.00M | -81.00M | -818.00M | 44.00M | 60.00M | -1.21B | -666.00M | 168.00M | 27.00M | 121.00M | 135.00M | 194.00M | 119.00M | 161.00M |
| Income Before Tax | 8.44B | 7.71B | 8.10B | -6.87B | 4.98B | 6.01B | 5.13B | 5.92B | 2.17B | 2.38B | 2.89B | 2.34B | 6.98B | 6.07B | 5.60B | 5.47B | 3.53B | 2.64B | 4.52B | 4.42B | 4.69B | 2.65B | 2.90B | 5.48B | 5.77B | 4.27B | 4.48B | 4.01B | 2.40B | 2.56B | 2.57B | 1.99B | 2.89B | 2.52B | 1.28B | 1.89B | 1.63B |
| Income Before Tax Ratio | 18.75% | 16.71% | 17.46% | -16.16% | 19.03% | 26.64% | 24.70% | 30.45% | 13.09% | 14.99% | 17.64% | 13.28% | 32.86% | 31.16% | 29.79% | 26.56% | 18.27% | 14.71% | 23.51% | 22.80% | 22.47% | 14.61% | 14.91% | 30.07% | 28.52% | 23.34% | 26.84% | 26.64% | 17.45% | 21.32% | 22.53% | 17.81% | 25.87% | 24.50% | 13.90% | 22.07% | 21.54% |
| Income Tax Expense | 400.00M | 1.37B | 1.08B | 2.12B | 1.52B | 1.03B | 4.16B | 1.41B | 477.00M | 352.00M | 311.00M | -161.00M | 1.72B | 1.56B | 1.18B | 1.32B | 803.00M | 610.00M | 932.00M | 1.52B | 1.22B | 435.00M | 459.00M | 1.38B | 1.60B | 1.13B | 1.28B | 1.16B | 590.00M | 713.00M | 612.00M | 449.00M | 831.00M | 776.00M | 530.00M | 635.00M | 560.00M |
| Net Income | 8.03B | 6.33B | 6.99B | -9.00B | 3.44B | 4.95B | 1.01B | 4.46B | 1.62B | 2.00B | 2.56B | 1.96B | 3.71B | 3.10B | 10.61B | 5.25B | 2.17B | 1.59B | 3.00B | 2.39B | 3.11B | 2.07B | 5.25B | 4.71B | 4.17B | 3.14B | 3.21B | 2.85B | 1.81B | 1.84B | 1.96B | 1.96B | 2.06B | 1.75B | 747.00M | 1.25B | 1.07B |
| Net Income Ratio | 17.83% | 13.71% | 15.08% | -21.16% | 13.15% | 21.95% | 4.85% | 22.94% | 9.81% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 25.47% | 11.19% | 8.85% | 15.62% | 12.32% | 14.87% | 11.40% | 27.00% | 25.86% | 20.61% | 17.18% | 19.19% | 18.92% | 13.16% | 15.37% | 17.16% | 17.59% | 18.42% | 16.97% | 8.13% | 14.65% | 14.13% |
| EPS | 3.88 | 2.97 | 3.15 | -3.98 | 2.02 | 3.03 | 0.61 | 2.67 | 0.97 | 1.21 | 1.56 | 1.17 | 2.18 | 1.81 | 5.38 | 2.65 | 1.10 | 0.81 | 1.54 | 1.23 | 1.60 | 1.03 | 2.70 | 2.40 | 2.10 | 1.58 | 1.61 | 1.42 | 0.90 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| EPS Diluted | 3.86 | 2.95 | 3.12 | -3.98 | 2.01 | 3.03 | 0.61 | 2.65 | 0.97 | 1.20 | 1.54 | 1.16 | 2.16 | 1.80 | 5.37 | 2.62 | 1.09 | 0.81 | 1.51 | 1.21 | 1.59 | 1.02 | 2.67 | 2.36 | 2.06 | 1.55 | 1.57 | 1.40 | 0.89 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| Weighted Avg Shares Out | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B | 1.67B | 1.66B | 1.64B | 1.67B | 1.70B | 1.71B | 1.97B | 1.98B | 1.97B | 1.96B | 1.95B | 1.94B | 1.94B | 2.00B | 1.94B | 1.97B | 1.98B | 1.99B | 1.99B | 2.01B | 2.02B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B | 1.72B | 1.73B | 1.98B | 2.00B | 1.98B | 1.96B | 1.98B | 1.98B | 1.95B | 2.02B | 1.97B | 2.00B | 2.03B | 2.03B | 2.04B | 2.04B | 2.03B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains
24/7 Wall St. Insights The long AI-driven rally has many tech stocks overvalued.
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial...
Initial Claims Lower-Than-Expected
Jobs Week trudges along this morning, with Friday morning's big Employment Situation report now on the horizon. Behind this stands the 2024 General Election — which could obviously sway the balance of executive and legislative branches of the U.S. government...
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street...
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $2 per share a year ago.
Bristol Myers's stock pops as earnings top estimates and company raises guidance
The company says it “made important strides in the third quarter.”
Bristol Myers Stock Rises After Earnings Beat, Guidance Hike
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs
Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid as well as newer drugs like heart treatment Camzyos and cancer cell therapy Breyanzi.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. The pharmaceutical giant also raised its full-year revenue and...
Source: https://incomestatements.info
Category: Stock Reports